<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>DROXIA- hydroxyureaÂ capsuleÂ </strong><br>E.R. Squibb &amp; Sons, L.L.C.<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use DROXIA safely and effectively. See full prescribing information for DROXIA.<br>DROXIA (hydroxyurea) capsules, for oral use<br>Initial U.S. Approval: 1967</div>
<div class="Warning"><div>
<h1 class="Warning">WARNING: <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">MYELOSUPPRESSION</span> AND MALIGNANCIES</h1>
<h1 class="Warning"><span class="Italics">See full prescribing information for complete boxed warning.</span></h1>
<dl>
<dt>Â </dt>
<dd>
<span class="Bold"><span class="Italics"><span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">Myelosuppression</span>:</span> DROXIA may cause severe <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">myelosuppression</span>. Do not give if bone marrow function is markedly depressed. Monitor blood counts at baseline and throughout treatment. Interrupt treatment and reduce dose as necessary. </span><span class="Bold"><a href="#ID_502ba289-7d05-4156-a275-60c0f7767a52">(5.1)</a></span>
</dd>
<dt>Â </dt>
<dd>
<span class="Bold"><span class="Italics">Malignancies:</span> Hydroxyurea is carcinogenic. Advise sun protection and monitor patients for malignancies. </span><span class="Bold"><a href="#ID_3454f21b-4d96-4d30-ad0d-d82da5e7c794">(5.2)</a></span>
</dd>
</dl>
</div></div>
<div></div>
<div class="Warning"><div>
<h1 class="Warning">WARNING: <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">MYELOSUPPRESSION</span> AND MALIGNANCIES</h1>
<h1 class="Warning"><span class="Italics">See full prescribing information for complete boxed warning.</span></h1>
<dl>
<dt>Â </dt>
<dd>
<span class="Bold"><span class="Italics"><span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">Myelosuppression</span>:</span> DROXIA may cause severe <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">myelosuppression</span>. Do not give if bone marrow function is markedly depressed. Monitor blood counts at baseline and throughout treatment. Interrupt treatment and reduce dose as necessary. </span><span class="Bold"><a href="#ID_502ba289-7d05-4156-a275-60c0f7767a52">(5.1)</a></span>
</dd>
<dt>Â </dt>
<dd>
<span class="Bold"><span class="Italics">Malignancies:</span> Hydroxyurea is carcinogenic. Advise sun protection and monitor patients for malignancies. </span><span class="Bold"><a href="#ID_3454f21b-4d96-4d30-ad0d-d82da5e7c794">(5.2)</a></span>
</dd>
</dl>
</div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div><p class="Highlighta">DROXIA is an antimetabolite indicated to reduce the frequency of painful crises and to reduce the need for blood transfusions in patients with <span class="product-label-link" type="condition" conceptid="22281" conceptname="Hb SS disease">sickle cell anemia</span> with recurrent moderate to severe painful crises. <a href="#ID_1cf30ce7-f31e-4913-a27d-b3fab80f3d92">(1)</a> </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><dl>
<dt>â€¢</dt>
<dd>Initial dose: 15 mg/kg/day as a single dose. The patientâ€™s blood count must be monitored every two weeks. <a href="#ID_731f938a-3b55-4572-aeab-9ba80a3b59a5">(2.1)</a>
</dd>
<dt>â€¢</dt>
<dd>The dose may be increased by 5 mg/kg/day every 12 weeks until a maximum tolerated dose or 35 mg/kg/day is reached if blood counts are in an acceptable range. <a href="#ID_731f938a-3b55-4572-aeab-9ba80a3b59a5">(2.1)</a>
</dd>
<dt>â€¢</dt>
<dd>The dose is not increased if blood counts are between the acceptable range and toxic. Discontinue DROXIA until hematologic recovery if blood counts are considered toxic. Treatment may then be resumed after reducing the dose by 2.5 mg/kg/day from the dose associated with hematological toxicity. <a href="#ID_731f938a-3b55-4572-aeab-9ba80a3b59a5">(2.1)</a>
</dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal impairment</span>: Reduce the dose of DROXIA by 50% in patients with creatinine clearance less than 60 mL/min. <a href="#ID_d1d8a6a6-aa48-4704-815b-970f86a0646f">(2.2</a>, <a href="#ID_e24758e4-d66f-47b9-a62c-cf47cc7b88b9">8.6</a>, <a href="#ID_34627130-d5a9-468c-9558-12df3057bb3f">12.3)</a>
</dd>
</dl></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><dl>
<dt>â€¢</dt>
<dd>Capsules: 200 mg, 300 mg, and 400 mg <a href="#ID_9ce019b6-2975-4292-a295-b44c36421523">(3)</a>
</dd>
</dl></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><dl>
<dt>â€¢</dt>
<dd>In patients who have demonstrated a previous <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to hydroxyurea or any other component of its formulation. <a href="#ID_881f1298-356a-4df0-95c6-9228e1453ae7">(4)</a>
</dd>
</dl></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><dl>
<dt>â€¢</dt>
<dd>Embryo-fetal toxicity: Can cause fetal harm. Advise of potential risk to a fetus and use of effective contraception. <a href="#ID_f192ba7c-bce6-4444-8461-a2cafd2183fd">(5.3</a>, <a href="#ID_45e3b835-f78e-412b-aa6d-68c56c9f65e7">8.1)</a>
</dd>
<dt>â€¢</dt>
<dd>Cutaneous vasculitic toxicities: Institute treatment and discontinue DROXIA if this occurs. <a href="#ID_791e94df-3d3e-4c72-8b39-ea84c2fac6c8">(5.4)</a>
</dd>
<dt>â€¢</dt>
<dd>Risks with concomitant use of antiretroviral drugs: <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">Pancreatitis</span>, hepatotoxicity, and <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">neuropathy</span> have occurred. Monitor for signs and symptoms in patients with <span class="product-label-link" type="condition" conceptid="439727" conceptname="Human immunodeficiency virus infection">HIV infection</span> using antiretroviral drugs; discontinue DROXIA, and implement treatment. <a href="#ID_859b8b26-81d0-4ff1-b2ec-e5f9aaeaf9de">(5.5)</a>
</dd>
</dl></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">Most common adverse reactions (â‰¥30%) are hematological, <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">gastrointestinal symptoms</span>, and <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>. <a href="#ID_f29e751b-8eed-4f76-ba31-7cd10f152b62">(6)</a> </p>
<p class="Highlighta">To report SUSPECTED ADVERSE REACTIONS, contact Bristol-Myers Squibb at 1-800-721-5072 or FDA at 1-800-FDA-1088 or <span class="Italics"><a href="http://www.fda.gov/medwatch">www.fda.gov/medwatch.</a></span> </p>
</div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><dl>
<dt>Â </dt>
<dd>Antiretroviral drugs.<a href="#ID_756ac625-bbee-43bd-8858-90d80e63a872">(7)</a>
</dd>
</dl></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div><div></div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><dl>
<dt>â€¢</dt>
<dd>
<span class="Italics">Nursing Mothers:</span> Hydroxyurea is excreted in human milk. Discontinue nursing during treatment with DROXIA. <a href="#ID_933a3c75-be9d-4768-8b00-0ebe868d4e13">(8.3)</a>
</dd>
</dl></div>
<div><div>
<div></div>
<div></div>
</div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div><div></div></div>
</div>
</div>
<div><div></div></div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.</p>
<p class="HighlightsRevision">Revised: 7/2015</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">WARNING: <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">MYELOSUPPRESSION</span> AND MALIGNANCIES</a></h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1Â  Dosing Information</a></h2>
<h2><a href="#section-2.2" class="toc">2.2 Dose Modifications for <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">Myelosuppression</span></a></h2>
<h2><a href="#section-5.2" class="toc">5.2 Malignancies</a></h2>
<h2><a href="#section-5.3" class="toc">5.3 Embryo-Fetal Toxicity</a></h2>
<h2><a href="#section-5.4" class="toc">5.4 Vasculitic Toxicities</a></h2>
<h2><a href="#section-5.5" class="toc">5.5 Risks with Concomitant Use of Antiretroviral Drugs</a></h2>
<h2><a href="#section-5.6" class="toc">5.6 <span class="product-label-link" type="condition" conceptid="4248718" conceptname="Macrocytosis">Macrocytosis</span></a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Clinical Trial Experience</a></h2>
<h2><a href="#section-6.2" class="toc">6.2 Postmarketing Experience</a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h2><a href="#section-7.1" class="toc">7.1 Increased Toxicity with Concomitant Use of Antiretroviral Drugs</a></h2>
<h2><a href="#section-7.2" class="toc">7.2 Test Interference</a></h2>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.3" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.4" class="toc">8.5 Geriatric Use</a></h2>
<h2><a href="#section-8.5" class="toc">8.6 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></a></h2>
<h2><a href="#section-8.6" class="toc">8.7 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></a></h2>
<h1><a href="#section-9" class="toc">10 OVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.3 Pharmacokinetics</a></h2>
<h1><a href="#section-12" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h1><a href="#section-13" class="toc">14 CLINICAL STUDIES</a></h1>
<h1><a href="#section-14" class="toc">15 REFERENCES</a></h1>
<h1><a href="#section-15" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h2><a href="#section-15.1" class="toc">16.1Â Â How Supplied</a></h2>
<h2><a href="#section-15.2" class="toc">16.2Â Â Storage</a></h2>
<h2><a href="#section-15.3" class="toc">16.3Â Â Handling and Disposal</a></h2>
<h1><a href="#section-16" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Warning">
<a name="ID_639271ee-5189-492d-b92f-6741b9539521"></a><a name="section-1"></a><p></p>
<h1>WARNING: <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">MYELOSUPPRESSION</span> AND MALIGNANCIES</h1>
<p class="First"><span class="Bold"><span class="Italics"><span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">Myelosuppression</span>:</span> DROXIA may cause severe <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">myelosuppression</span>. Monitor blood counts at baseline and throughout treatment. Interrupt treatment and reduce dose as necessary <span class="Italics">[see <a href="#ID_502ba289-7d05-4156-a275-60c0f7767a52">Warnings and Precautions (5.1)</a>]</span>.</span></p>
<p><span class="Bold"><span class="Italics">Malignancies:</span> Hydroxyurea is carcinogenic. Advise sun protection and monitor patients for malignancies <span class="Italics">[see <a href="#ID_3454f21b-4d96-4d30-ad0d-d82da5e7c794">Warnings and Precautions (5.2)</a>]</span>.</span></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="ID_1cf30ce7-f31e-4913-a27d-b3fab80f3d92"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<p class="First">DROXIA is indicated to reduce the frequency of painful crises and to reduce the need for blood transfusions in patients with <span class="product-label-link" type="condition" conceptid="22281" conceptname="Hb SS disease">sickle cell anemia</span> with recurrent moderate to severe painful crises.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="ID_bf433a3e-9bd9-4d8e-81f0-0d6311989f1e"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_731f938a-3b55-4572-aeab-9ba80a3b59a5"></a><a name="section-2.1"></a><p></p>
<h2>2.1Â  Dosing Information</h2>
<table cellpadding="5.75pt" width="100%">
<caption><span>Table 1:Â Â Â Â Â Dosing Recommendation Based on Blood Count</span></caption>
<col width="21%">
<col width="23%">
<col width="27%">
<col width="29%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Toprule"><p class="First"><span class="Bold">Dosing Regimen</span></p></td>
<td class="Botrule Toprule" align="center"><p class="First"><span class="Bold">Dose</span></p></td>
<td class="Botrule Toprule" align="center"><p class="First"><span class="Bold">Dose Modification Criteria</span></p></td>
<td class="Botrule Toprule" align="center"><p class="First"><span class="Bold">Monitoring Parameters</span></p></td>
</tr>
<tr>
<td class="Botrule Toprule"><p class="First"><span class="Bold">Initial Recommended<br>Dosing</span></p></td>
<td class="Botrule"><p class="First">15 mg/kg/day as a single dose</p></td>
<td class="Botrule">
<p class="First">Base dosage on the patientâ€™s actual or ideal weight, whichever is less.</p>
<p>Monitor the patientâ€™s blood count every 2 weeks <span class="Italics">[see <a href="#ID_502ba289-7d05-4156-a275-60c0f7767a52">Warnings and Precautions (5.1)</a>]</span>.</p>
</td>
<td class="Botrule"></td>
</tr>
<tr>
<td class="Botrule Toprule"><p class="First"><span class="Bold">Dosing Based on <br>Blood Counts</span></p></td>
<td class="Botrule Toprule"></td>
<td class="Botrule Toprule"></td>
<td class="Botrule Toprule"></td>
</tr>
<tr>
<td class="Botrule Toprule"><p class="First">Â Â In an acceptable<br>Â Â range</p></td>
<td class="Botrule Toprule">
<p class="First">Increase dose<br>5Â mg/kg/day every 12 weeks</p>
<p>Maximal dose:<br>35 mg/kg/day*</p>
<p>*Maximal dose is the highest dose that does not produce <span class="Bold">toxic</span> blood counts over 24 consecutive weeks.</p>
</td>
<td class="Botrule Toprule">
<p class="First">Increase dosing only if blood counts are in an acceptable range.</p>
<p>Do not increase if <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">myelosuppression</span> occurs.</p>
</td>
<td class="Botrule Toprule">
<p class="First"><span class="Bold">Blood Counts Acceptable Range</span></p>
<p><span class="product-label-link" type="condition" conceptid="4148615" conceptname="Neutrophil count">neutrophils</span> â‰¥2500 cells/mm<span class="Sup">3</span></p>
<p>platelets â‰¥95,000/mm<span class="Sup">3</span></p>
<p>hemoglobin &gt;5.3 g/dL</p>
<p>reticulocytes â‰¥95,000/mm<span class="Sup">3</span> if <br>Â Â Â Â the hemoglobin<br>Â Â Â Â concentration &lt;9 g/dL</p>
</td>
</tr>
<tr>
<td class="Botrule Toprule"><p class="First">Â Â BetweenÂ acceptable<br>Â Â and toxic range</p></td>
<td class="Botrule Toprule"><p class="First">Do not increase dose.</p></td>
<td class="Botrule Toprule"><p class="First">If blood counts are considered <span class="Bold">toxic</span>, discontinue DROXIA until hematologic recovery.</p></td>
<td class="Botrule Toprule">
<p class="First"><span class="Bold">Blood Counts Toxic Range</span></p>
<p><span class="product-label-link" type="condition" conceptid="4148615" conceptname="Neutrophil count">neutrophils</span> &lt;2000 cells/mm<span class="Sup">3</span></p>
<p>platelets &lt;80,000/mm<span class="Sup">3</span></p>
<p>hemoglobin &lt;4.5 g/dL</p>
<p>reticulocytes &lt;80,000/mm<span class="Sup">3</span> if <br>Â Â Â Â the hemoglobin <br>Â Â Â Â concentration &lt;9 g/dL</p>
</td>
</tr>
<tr class="Last">
<td class="Botrule Toprule"><p class="First"><span class="Bold">Dosing After <br>Hematologic <br>Recovery</span></p></td>
<td class="Botrule Toprule"><p class="First">Reduce dose by<br>2.5 mg/kg/day.</p></td>
<td class="Botrule Toprule">
<p class="First">Reduce the dose from the dose associated with hematologic toxicity.</p>
<p>May titrate up or down every 12 weeks in 2.5 mg/kg/day increments.</p>
<p>The patient should be at a stable dose with no hematologic toxicity for 24 weeks.</p>
<p>Discontinue the treatment permanently if a patient develops hematologic toxicity twice.</p>
</td>
<td class="Botrule Toprule"></td>
</tr>
</tbody>
</table>
<p class="First">Patients must be able to follow directions regarding drug administration and their monitoring and care.</p>
<p>Fetal hemoglobin (HbF) levels may be used to evaluate the efficacy of DROXIA in clinical use. Obtain HbF levels every three to four months. Monitor for an increase in HbF of at least two-fold over the baseline value.</p>
<p>DROXIA causes <span class="product-label-link" type="condition" conceptid="4248718" conceptname="Macrocytosis">macrocytosis</span>, which may mask the incidental development of <span class="product-label-link" type="condition" conceptid="4101280" conceptname="Folic acid deficiency">folic acid deficiency</span>. <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">Prophylactic</span> administration of folic acid is recommended.</p>
<p>DROXIA is a cytotoxic drug. Follow applicable special handling and disposal procedures <span class="Italics">[see <a href="#ID_8b8068d8-4385-4819-8395-3a3611a202a0">References (15)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_d1d8a6a6-aa48-4704-815b-970f86a0646f"></a><a name="section-2.2"></a><p></p>
<h2>2.2 Dose Modifications for <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<p class="First">Reduce the dose of DROXIA by 50% in patients with creatinine clearance of less than 60Â mL/min or with end-stage <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span> (ESRD) <span class="Italics">[see <a href="#ID_e24758e4-d66f-47b9-a62c-cf47cc7b88b9">Use in Specific Populations (8.6)</a> and <a href="#ID_34627130-d5a9-468c-9558-12df3057bb3f">Clinical Pharmacology (12.3)</a>]</span>. Creatinine clearance values were obtained using 24-hour urine collections.</p>
<table width="85%">
<col width="34%">
<col width="64%">
<tfoot><tr class="First Last"><td class="Botrule" align="left" colspan="2" valign="top">*Â Â On dialysis days, administer DROXIA to patients with ESRD following hemodialysis.</td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center">
<p class="First"><span class="Bold">Creatinine Clearance</span></p>
<p><span class="Bold">(mL/min)</span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center">
<p class="First"><span class="Bold">Recommended DROXIA Initial Dose</span></p>
<p><span class="Bold">(mg/kg daily)</span></p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center"><p class="First">â‰¥60</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">15</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">&lt;60 or ESRD*</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">7.5</p></td>
</tr>
</tbody>
</table>
<p>Monitor the hematologic parameters closely in these patients.</p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="ID_9ce019b6-2975-4292-a295-b44c36421523"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">Capsules:</p>
<dl>
<dt>â€¢</dt>
<dd>200 mg opaque blue-green capsules, imprinted with black ink â€œDROXIAâ€? and â€œ6335.â€?</dd>
<dt>â€¢</dt>
<dd>300 mg opaque purple capsules, imprinted with black ink â€œDROXIAâ€? and â€œ6336.â€?</dd>
<dt>â€¢</dt>
<dd>400 mg opaque reddish-orange capsules, imprinted with black ink â€œDROXIAâ€? and â€œ6337.â€?</dd>
</dl>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="ID_881f1298-356a-4df0-95c6-9228e1453ae7"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<p class="First">DROXIA is contraindicated in patients who have demonstrated a previous <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to hydroxyurea or any other component of its formulation.</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="ID_2bda9cce-85da-426e-9e90-14fa6ff39873"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_502ba289-7d05-4156-a275-60c0f7767a52"></a><a name="section-5.1"></a><p></p>
<h2>5.1 <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">Myelosuppression</span></h2>
<p class="First">Hydroxyurea causes severe <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">myelosuppression</span>. Treatment with hydroxyurea should not be initiated if bone marrow function is markedly depressed. Bone marrow suppression may occur, and <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span> is generally its first and most common manifestation. <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">Thrombocytopenia</span> and <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> occur less often, and are seldom seen without a preceding <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>.</p>
<p>Some patients, treated at the recommended initial dose of 15 mg/kg/day, have experienced severe or life-threatening <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">myelosuppression</span>.</p>
<p>Evaluate hematologic status prior to and during treatment with DROXIA. Provide supportive care and modify dose or discontinue DROXIA as needed. Recovery from <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">myelosuppression</span> is usually rapid when therapy is interrupted.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_3454f21b-4d96-4d30-ad0d-d82da5e7c794"></a><a name="section-5.2"></a><p></p>
<h2>5.2 Malignancies</h2>
<p class="First">Hydroxyurea is a human carcinogen. In patients receiving long-term hydroxyurea for <span class="product-label-link" type="condition" conceptid="4175485" conceptname="Myeloproliferative disorder">myeloproliferative disorders</span>, secondary <span class="product-label-link" type="condition" conceptid="315497" conceptname="Subacute leukemia">leukemia</span> has been reported<span class="Italics">.</span> Skin cancer has also been reported in patients receiving long-term hydroxyurea. Advise protection from sun exposure and monitor for the development of secondary malignancies.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_f192ba7c-bce6-4444-8461-a2cafd2183fd"></a><a name="section-5.3"></a><p></p>
<h2>5.3 Embryo-Fetal Toxicity</h2>
<p class="First">Hydroxyurea may cause fetal harm when administered to a pregnant woman. Hydroxyurea is genotoxic. Hydroxyurea has been demonstrated to be a potent teratogen in a wide variety of animal models, including mice, hamsters, cats, miniature swine, dogs, and monkeys at doses within 1-fold of the human dose given on a mg/m<span class="Sup">2</span> basis. Hydroxyurea is embryotoxic and causes <span class="product-label-link" type="condition" conceptid="4079975" conceptname="Congenital malformation">fetal malformations</span> at 180 mg/kg/day in rats and at 30 mg/kg/day in rabbits. Single doses of â‰¥375 mg/kg to rats caused <span class="product-label-link" type="condition" conceptid="4245750" conceptname="Growth retardation">growth retardation</span> and impaired learning ability. Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during and after treatment with DROXIA for at least 30 days after therapy. Females of reproductive potential should also ensure that their male partner, who is/has taken DROXIA, uses effective contraception during and after treatment for at least 1 year after therapy. Advise males of reproductive potential to use effective contraception during and after treatment with DROXIA for at least 1 year after therapy <span class="Italics">[see <a href="#ID_45e3b835-f78e-412b-aa6d-68c56c9f65e7">Use in Specific Populations (8.1</a>, <a href="#ID_933a3c75-be9d-4768-8b00-0ebe868d4e13">8.3)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_791e94df-3d3e-4c72-8b39-ea84c2fac6c8"></a><a name="section-5.4"></a><p></p>
<h2>5.4 Vasculitic Toxicities</h2>
<p class="First">Cutaneous vasculitic toxicities, including vasculitic ulcerations and <span class="product-label-link" type="condition" conceptid="439928" conceptname="Gangrenous disorder">gangrene</span>, have occurred in patients with <span class="product-label-link" type="condition" conceptid="4175485" conceptname="Myeloproliferative disorder">myeloproliferative disorders</span> during therapy with hydroxyurea. These vasculitic toxicities were reported most often in patients with a history of, or currently receiving, interferon therapy. If cutaneous vasculitic <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcers</span> occur, institute treatment and discontinue DROXIA.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_859b8b26-81d0-4ff1-b2ec-e5f9aaeaf9de"></a><a name="section-5.5"></a><p></p>
<h2>5.5 Risks with Concomitant Use of Antiretroviral Drugs</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">Pancreatitis</span>, hepatotoxicity, and <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">peripheral neuropathy</span> have occurred when hydroxyurea was administered concomitantly with antiretroviral drugs, including didanosine and stavudine <span class="Italics">[see <a href="#ID_89b29ad3-8e67-4a0b-925e-57a8648102c1">Drug Interactions (7.1)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_663e7cab-fa0b-47ca-867a-a78c01965275"></a><a name="section-5.6"></a><p></p>
<h2>5.6 <span class="product-label-link" type="condition" conceptid="4248718" conceptname="Macrocytosis">Macrocytosis</span></h2>
<p class="First">DROXIA may cause <span class="product-label-link" type="condition" conceptid="4248718" conceptname="Macrocytosis">macrocytosis</span>, which is self-limiting, and is often seen early in the course of treatment. The morphologic change resembles <span class="product-label-link" type="condition" conceptid="432295" conceptname="Pernicious anemia">pernicious anemia</span>, but is not related to vitamin B<span class="Sub">12</span> or <span class="product-label-link" type="condition" conceptid="4101280" conceptname="Folic acid deficiency">folic acid deficiency</span>. This may mask the diagnosis of <span class="product-label-link" type="condition" conceptid="432295" conceptname="Pernicious anemia">pernicious anemia</span>. <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">Prophylactic</span> administration of folic acid is recommended.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="ID_f29e751b-8eed-4f76-ba31-7cd10f152b62"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<p class="First">The following adverse reactions are described in detail in other labeling sections:</p>
<dl>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">Myelosuppression</span> <span class="Italics">[see <a href="#ID_502ba289-7d05-4156-a275-60c0f7767a52">Warnings and Precautions (5.1)</a>]</span>
</dd>
<dt>â€¢</dt>
<dd>Malignancies <span class="Italics">[see <a href="#ID_3454f21b-4d96-4d30-ad0d-d82da5e7c794">Warnings and Precautions (5.2)</a>]</span>
</dd>
<dt>â€¢</dt>
<dd>Embryo-fetal toxicity <span class="Italics">[see <a href="#ID_639271ee-5189-492d-b92f-6741b9539521">Boxed Warning</a> and <a href="#ID_f192ba7c-bce6-4444-8461-a2cafd2183fd">Warnings and Precautions (5.3)</a>]</span>
</dd>
<dt>â€¢</dt>
<dd>Vasculitic toxicities <span class="Italics">[see <a href="#ID_791e94df-3d3e-4c72-8b39-ea84c2fac6c8">Warnings and Precautions (5.4)</a>]</span>
</dd>
<dt>â€¢</dt>
<dd>Risks with concomitant use of antiretroviral drugs <span class="Italics">[see <a href="#ID_859b8b26-81d0-4ff1-b2ec-e5f9aaeaf9de">Warnings and Precautions (5.5)</a>]</span>
</dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="4248718" conceptname="Macrocytosis">Macrocytosis</span> <span class="Italics">[see <a href="#ID_663e7cab-fa0b-47ca-867a-a78c01965275">Warnings and Precautions (5.6)</a>]</span>
</dd>
</dl>
<p>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_6b2e2f4c-49e6-4489-85d6-c1e77a6bee45"></a><a name="section-6.1"></a><p></p>
<h2>6.1 Clinical Trial Experience</h2>
<p class="First">In 299 patients treated for <span class="product-label-link" type="condition" conceptid="22281" conceptname="Hb SS disease">sickle cell anemia</span> in the Multicenter Study of Hydroxyurea in <span class="product-label-link" type="condition" conceptid="22281" conceptname="Hb SS disease">Sickle Cell Anemia</span>, the most common adverse reactions were hematologic, with <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, and low reticulocyte and platelet levels necessitating temporary cessation in almost all patients. Hematologic recovery usually occurred in two weeks.</p>
<p>Other adverse reactions include <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">hair loss</span>, <span class="product-label-link" type="condition" conceptid="4248718" conceptname="Macrocytosis">macrocytosis</span>, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, and <span class="product-label-link" type="condition" conceptid="4297821" conceptname="Melanonychia">melanonychia</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_d32e1878-df62-418d-a60d-b662f831dde0"></a><a name="section-6.2"></a><p></p>
<h2>6.2 Postmarketing Experience</h2>
<p class="First">The following adverse reactions have been identified during postapproval use of hydroxyurea in the treatment of neoplastic diseases. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency.</p>
<dl>
<dt>â€¢</dt>
<dd>
<span class="Italics"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">stomatitis</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, and <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span></dd>
<dt>â€¢</dt>
<dd>
<span class="Italics">Skin and subcutaneous tissue disorders:</span> <span class="product-label-link" type="condition" conceptid="4083795" conceptname="Maculopapular eruption">maculopapular rash</span>, <span class="product-label-link" type="condition" conceptid="4262920" conceptname="Skin ulcer">skin ulceration</span>, <span class="product-label-link" type="condition" conceptid="80182" conceptname="Dermatomyositis">dermatomyositis</span>-like skin changes, peripheral and facial <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>, hyperpigmentation, <span class="product-label-link" type="condition" conceptid="4028206" conceptname="Atrophy">atrophy</span> of skin and nails, scaling, violet <span class="product-label-link" type="condition" conceptid="4105835" conceptname="Papule">papules</span>, and <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span></dd>
<dt>â€¢</dt>
<dd>
<span class="Italics">Renal and urinary disorders:</span> <span class="product-label-link" type="condition" conceptid="197684" conceptname="Dysuria">dysuria</span>, elevations in serum uric acid, blood urea nitrogen (BUN), and creatinine levels</dd>
<dt>â€¢</dt>
<dd>
<span class="Italics"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous system disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, <span class="product-label-link" type="condition" conceptid="4011527" conceptname="Spatial disorientation">disorientation</span>, <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>, and <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span></dd>
<dt>â€¢</dt>
<dd>
<span class="Italics">General disorders:</span> <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span>, <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, and <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span></dd>
<dt>â€¢</dt>
<dd>
<span class="Italics">Hepatobiliary disorders:</span> elevation of hepatic enzymes</dd>
<dt>â€¢</dt>
<dd>
<span class="Italics"><span class="product-label-link" type="condition" conceptid="320136" conceptname="Disorder of respiratory system">Respiratory disorders</span>:</span> diffuse pulmonary infiltrates, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, and <span class="product-label-link" type="condition" conceptid="4197819" conceptname="Fibrosis of lung">pulmonary fibrosis</span></dd>
</dl>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="ID_756ac625-bbee-43bd-8858-90d80e63a872"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_89b29ad3-8e67-4a0b-925e-57a8648102c1"></a><a name="section-7.1"></a><p></p>
<h2>7.1 Increased Toxicity with Concomitant Use of Antiretroviral Drugs</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_89c1c93f-d210-46c3-88b7-e918e784efe9"></a><a name="section-7.1.1"></a><p></p>
<h3><span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">Pancreatitis</span></h3>
<p class="First">In patients with <span class="product-label-link" type="condition" conceptid="439727" conceptname="Human immunodeficiency virus infection">HIV infection</span> during therapy with hydroxyurea and didanosine, with or without stavudine<span class="Italics">,</span> fatal and nonfatal <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span> have occurred. Hydroxyurea is not indicated for the treatment of <span class="product-label-link" type="condition" conceptid="439727" conceptname="Human immunodeficiency virus infection">HIV infection</span>; however, if patients with <span class="product-label-link" type="condition" conceptid="439727" conceptname="Human immunodeficiency virus infection">HIV infection</span> are treated with hydroxyurea, and in particular, in combination with didanosine and/or stavudine, close monitoring for signs and symptoms of <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span> is recommended. Permanently discontinue therapy with hydroxyurea in patients who develop signs and symptoms of <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_30c972e3-b9c1-4195-867b-0202be522b74"></a><a name="section-7.1.2"></a><p></p>
<h3>Hepatotoxicity</h3>
<p class="First">Hepatotoxicity and <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic failure</span> resulting in <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> have been reported during postmarketing surveillance in patients with <span class="product-label-link" type="condition" conceptid="439727" conceptname="Human immunodeficiency virus infection">HIV infection</span> treated with hydroxyurea and other antiretroviral drugs. Fatal hepatic events were reported most often in patients treated with the combination of hydroxyurea, didanosine, and stavudine. Avoid this combination.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_6f6a8250-59d1-4ef1-9f70-300527466b81"></a><a name="section-7.1.3"></a><p></p>
<h3><span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">Peripheral Neuropathy</span></h3>
<p class="First"><span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">Peripheral neuropathy</span>, which was severe in some cases, has been reported in patients with <span class="product-label-link" type="condition" conceptid="439727" conceptname="Human immunodeficiency virus infection">HIV infection</span> receiving hydroxyurea in combination with antiretroviral drugs, including didanosine, with or without stavudine.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_14445de8-106e-4966-bc99-891f71a40ed5"></a><a name="section-7.2"></a><p></p>
<h2>7.2 Test Interference</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_ed713cfc-3d6a-4727-b7e1-623185a64c19"></a><a name="section-7.2.1"></a><p></p>
<h3>Interference with Uric Acid, Urea, or Lactic Acid Assays</h3>
<p class="First">Studies have shown that there is an analytical interference of hydroxyurea with the enzymes (urease, uricase, and lactate dehydrogenase) used in the determination of urea, uric acid, and lactic acid, rendering falsely elevated results of these in patients treated with hydroxyurea.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="ID_263cda6a-5c5c-4916-9c2d-0f0cd2b3db68"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="ID_45e3b835-f78e-412b-aa6d-68c56c9f65e7"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_c455ba03-98ee-4cde-bd28-bb9ed7129bcb"></a><a name="section-8.1.1"></a><p></p>
<h3>Pregnancy Category D</h3>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_b8131a89-b381-470b-b3f5-2bdc3a844e8d"></a><a name="section-8.1.1.1"></a><p></p>
<h4>Risk Summary</h4>
<p class="First">DROXIA may cause fetal harm when administered to a pregnant woman. There are no adequate and well-controlled studies in pregnant women. If this drug is used during pregnancy or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential harm to the fetus. Women of childbearing potential should be advised to avoid becoming pregnant.</p>
<p>Drugs which affect DNA synthesis, such as hydroxyurea, may be potential mutagenic agents.</p>
<p>The physician should carefully consider this possibility before administering this drug to male or female patients who may contemplate conception <span class="Italics">[see <a href="#ID_f192ba7c-bce6-4444-8461-a2cafd2183fd">Warnings and Precautions (5.3)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_e5a9dce2-dfc7-4671-8230-58f687c875ce"></a><a name="section-8.1.1.2"></a><p></p>
<h4>Animal Data</h4>
<p class="First">Hydroxyurea has been demonstrated to be a potent teratogen in a wide variety of animal models, including mice, hamsters, cats, miniature swine, dogs, and monkeys at doses within 1-fold of the human dose given on a mg/m<span class="Sup">2</span> basis. Hydroxyurea is embryotoxic and causes <span class="product-label-link" type="condition" conceptid="4079975" conceptname="Congenital malformation">fetal malformations</span> (partially ossified cranial bones, absence of eye sockets, <span class="product-label-link" type="condition" conceptid="4043738" conceptname="Hydrocephalus">hydrocephaly</span>, bipartite sternebrae, missing lumbar vertebrae) at 180 mg/kg/day (about 0.8 times the maximum recommended human daily dose on a mg/m<span class="Sup">2</span> basis) in rats and at 30 mg/kg/day (about 0.3 times the maximum recommended human daily dose on a mg/m<span class="Sup">2</span> basis) in rabbits. Embryotoxicity was characterized by decreased fetal viability, reduced live litter sizes, and <span class="product-label-link" type="condition" conceptid="436077" conceptname="Developmental delay">developmental delays</span>. Hydroxyurea crosses the placenta. Single doses of â‰¥375 mg/kg (about 1.7 times the maximum recommended human daily dose on a mg/m<span class="Sup">2</span> basis) to rats caused <span class="product-label-link" type="condition" conceptid="4245750" conceptname="Growth retardation">growth retardation</span> and impaired learning ability.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="ID_933a3c75-be9d-4768-8b00-0ebe868d4e13"></a><a name="section-8.2"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">Hydroxyurea is excreted in human milk. Because of the potential for serious adverse reactions with hydroxyurea, discontinue nursing during treatment with DROXIA.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="ID_66bd821f-41c9-4a3c-9ab2-68eed509b66d"></a><a name="section-8.3"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">Safety and effectiveness in pediatric patients have not been established.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_20d4540f-a702-441d-a677-5a536633b5df"></a><a name="section-8.4"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First">Clinical studies of DROXIA did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects.</p>
<p>Elderly patients may be more sensitive to the effects of hydroxyurea, and may require a lower dose regimen. Hydroxyurea is excreted by the kidney, and the risk of adverse reactions to this drug may be greater in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function<span class="Italics"> [see <a href="#ID_d1d8a6a6-aa48-4704-815b-970f86a0646f">Dosage and Administration (2.2)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_e24758e4-d66f-47b9-a62c-cf47cc7b88b9"></a><a name="section-8.5"></a><p></p>
<h2>8.6 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<p class="First">The exposure to hydroxyurea is higher in patients with creatinine clearance of less than 60Â mL/min. Reduce dosage and closely monitor the hematologic parameters when DROXIA is to be administered to these patients<span class="Italics"> [see <a href="#ID_d1d8a6a6-aa48-4704-815b-970f86a0646f">Dosage and Administration (2.2)</a> and <a href="#ID_34627130-d5a9-468c-9558-12df3057bb3f">Clinical Pharmacology (12.3)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_bc4195b3-2a7c-4ab7-91c7-a8e777c13e93"></a><a name="section-8.6"></a><p></p>
<h2>8.7 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></h2>
<p class="First">There are no data that support specific guidance for dosage adjustment in patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>. Close monitoring of hematologic parameters is advised in these patients.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="ID_884f1ddf-27ee-41e1-9696-7be47d28e5af"></a><a name="section-9"></a><p></p>
<h1>10 OVERDOSAGE</h1>
<p class="First">Acute mucocutaneous toxicity has been reported in patients receiving hydroxyurea at dosages several times the therapeutic dose. Soreness, violet <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> on palms and soles followed by scaling of hands and feet, severe generalized hyperpigmentation of the skin, and <span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">stomatitis</span> have been observed.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="ID_cadb62a6-8d28-4b11-86ac-1e2139941291"></a><a name="section-10"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">DROXIA<span class="Sup">Â®</span> (hydroxyurea capsules, USP) is available for oral use as capsules containing 200 mg, 300Â mg, and 400 mg hydroxyurea. Inactive ingredients include citric acid, gelatin, lactose, magnesium stearate, sodium phosphate, titanium dioxide, and capsule colorants: FD&amp;C Blue No. 1 and FD&amp;C Green No. 3 (200 mg capsules); D&amp;C Red No. 28, D&amp;C Red No. 33, and FD&amp;C Blue No. 1 (300 mg capsules); D&amp;C Red No. 28, D&amp;C Red No. 33, and D&amp;C Yellow No. 10 (400 mg capsules).</p>
<p>Hydroxyurea is a white crystalline powder. It has a molecular weight of 76.05. Its structural formula is:</p>
<div class="Figure">
<a name="id16936187"></a><img alt="Hydroxyurea Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=740e054b-faac-7c27-f06d-a56efb699355&amp;name=image-01.jpg">
</div>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="ID_fd6ec624-3625-40f9-bb01-7edf93d3cfb1"></a><a name="section-11"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="ID_554ab8d8-dbbb-440c-a8af-b3a8ad368194"></a><a name="section-11.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">The precise mechanism by which hydroxyurea produces its cytotoxic and cytoreductive effects is not known. However, various studies support the hypothesis that hydroxyurea causes an immediate inhibition of DNA synthesis by acting as a ribonucleotide reductase inhibitor, without interfering with the synthesis of ribonucleic acid or of protein.</p>
<p>The mechanisms by which DROXIA produces its beneficial effects in patients with <span class="product-label-link" type="condition" conceptid="22281" conceptname="Hb SS disease">sickle cell anemia</span> (SCA) are uncertain. Known pharmacologic effects of DROXIA that may contribute to its beneficial effects include increasing hemoglobin F levels in red blood cells (RBCs), decreasing <span class="product-label-link" type="condition" conceptid="4148615" conceptname="Neutrophil count">neutrophils</span>, increasing the water content of RBCs, increasing deformability of sickled cells, and altering the <span class="product-label-link" type="condition" conceptid="4175338" conceptname="Adhesion">adhesion</span> of RBCs to endothelium.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="ID_34627130-d5a9-468c-9558-12df3057bb3f"></a><a name="section-11.2"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_0186b2cf-c046-40e6-b522-0cb1476cc27b"></a><a name="section-11.2.1"></a><p></p>
<h3>Absorption</h3>
<p class="First">Following oral administration of DROXIA, hydroxyurea reaches peak plasma concentrations in 1 to 4 hours. Mean peak plasma concentrations and AUCs increase more than proportionally with increase of dose.</p>
<p>There are no data on the effect of food on the absorption of hydroxyurea.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_a3dc4e98-9651-4e4d-bb78-6090ea0e86c9"></a><a name="section-11.2.2"></a><p></p>
<h3>Distribution</h3>
<p class="First">Hydroxyurea distributes throughout the body with a volume of distribution approximating total body water.</p>
<p>Hydroxyurea concentrates in leukocytes and erythrocytes.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_aaeeabe2-71de-4e4f-9c65-a360d975f8d0"></a><a name="section-11.2.3"></a><p></p>
<h3>Metabolism</h3>
<p class="First">Up to 60% of an oral dose undergoes conversion through saturable hepatic metabolism and a minor pathway of degradation by urease found in intestinal bacteria.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_ec10338e-80c6-46f7-8e21-981fbf8c70e9"></a><a name="section-11.2.4"></a><p></p>
<h3>Excretion</h3>
<p class="First">In patients with <span class="product-label-link" type="condition" conceptid="22281" conceptname="Hb SS disease">sickle cell anemia</span>, the mean cumulative urinary recovery of hydroxyurea was about 40% of the administered dose.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_ce4de506-7e4f-427d-8994-8c571beba17e"></a><a name="section-11.2.5"></a><p></p>
<h3>Specific Populations</h3>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_f919b0de-0ffb-4456-a40b-3b76e461083a"></a><a name="section-11.2.5.1"></a><p></p>
<h4><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h4>
<p class="First">The effect of <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> on the pharmacokinetics of hydroxyurea was assessed in adult patients with <span class="product-label-link" type="condition" conceptid="22281" conceptname="Hb SS disease">sickle cell disease</span> and <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. Patients with normal renal function (creatinine clearance [CrCl] &gt;80Â mL/min), mild (CrCl 50-80Â mL/min), moderate (CrCl =30-&lt;50Â mL/min), or severe (&lt;30Â mL/min) <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> received a single oral dose of 15Â mg/kg hydroxyurea. Creatinine clearance values were obtained using 24-hour urine collections. Patients with ESRD received two doses of 15Â mg/kg separated by 7 days; the first was given following a 4-hour hemodialysis session, the second prior to hemodialysis. The exposure to hydroxyurea (mean AUC) in patients with CrCl &lt;60 mL/min and those with ESRD was 64% higher than in patients with normal renal function (CrCl &gt;60Â mL/min). Reduce the dose of DROXIA when it is administered to patients with creatinine clearance of &lt;60 mL/min or with ESRD following hemodialysis<span class="Italics"> [see </span><span class="Italics"><a href="#ID_d1d8a6a6-aa48-4704-815b-970f86a0646f">Dosage and Administration (2.2)</a></span><span class="Italics"> and <a href="#ID_e24758e4-d66f-47b9-a62c-cf47cc7b88b9">Use in Specific Populations (8.6)</a>]</span>.</p>
</div>
</div>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="ID_14bddc67-fa8a-49f5-8454-106e4b14befc"></a><a name="section-12"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_5cbe915a-9172-48d4-b099-665f42dba801"></a><a name="section-12.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">See <span class="Italics"><a href="#ID_639271ee-5189-492d-b92f-6741b9539521">Boxed Warning</a></span> and <a href="#ID_3454f21b-4d96-4d30-ad0d-d82da5e7c794">Warnings and Precautions (5.2)</a> for carcinogenesis and mutagenesis information.</p>
<p>Conventional long-term studies to evaluate the carcinogenic potential of DROXIA have not been performed. However, intraperitoneal administration of 125 to 250 mg/kg hydroxyurea (about 0.6-1.2 times the maximum recommended human oral daily dose on a mg/m<span class="Sup">2</span> basis) thrice weekly for 6 months to female rats increased the incidence of mammary tumors in rats surviving to 18 months compared to control. Hydroxyurea is mutagenic <span class="Italics">in vitro</span> to bacteria, fungi, protozoa, and mammalian cells. Hydroxyurea is clastogenic <span class="Italics">in vitro</span> (hamster cells, human lymphoblasts) and <span class="Italics">in vivo</span> (SCE assay in rodents, mouse micronucleus assay). Hydroxyurea causes the transformation of rodent embryo cells to a tumorigenic phenotype.</p>
<p><span class="Italics">Impairment of Fertility:</span> Hydroxyurea administered to male rats at 60Â mg/kg/day (about 0.3 times the maximum recommended human daily dose on a mg/m<span class="Sup">2</span> basis) produced <span class="product-label-link" type="condition" conceptid="438477" conceptname="Atrophy of testis">testicular atrophy</span>, decreased spermatogenesis, and significantly reduced their ability to impregnate females.</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="ID_e0cd9886-4f79-43f1-86ca-84d18ae30832"></a><a name="section-13"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<p class="First">The efficacy of hydroxyurea in <span class="product-label-link" type="condition" conceptid="22281" conceptname="Hb SS disease">sickle cell anemia</span> was assessed in a large clinical study (Multicenter Study of Hydroxyurea in <span class="product-label-link" type="condition" conceptid="22281" conceptname="Hb SS disease">Sickle Cell Anemia</span>) (see Table 2).</p>
<p>The study was a randomized, double-blind, placebo-controlled trial that evaluated 299 adult patients (â‰¥18 years) with moderate to severe disease (â‰¥3 painful crises yearly). The trial was stopped by the Data Safety Monitoring Committee, after accrual was completed but before the scheduled 24 months of follow-up was completed in all patients, based on observations of fewer painful crises among patients receiving hydroxyurea.</p>
<p>Compared to placebo treatment, treatment with hydroxyurea resulted in a significant decrease in the yearly rate of painful crises, the yearly rate of painful crises requiring hospitalization, the incidence of chest syndrome, the number of patients transfused, and units of blood transfused. Hydroxyurea treatment significantly increased the median time to both first and second painful crises.</p>
<p>Although patients with 3 or more painful crises during the preceding 12 months were eligible for the study, most of the benefit in crisis reduction was seen in the patients with 6 or more painful crises during the preceding 12 months.</p>
<table width="100%">
<caption><span>Table 2:Â Â Â Â Â Results from the Multicenter Study of Hydroxyurea in <span class="product-label-link" type="condition" conceptid="22281" conceptname="Hb SS disease">Sickle Cell Anemia</span></span></caption>
<col width="31%">
<col width="20%">
<col width="16%">
<col width="21%">
<col width="12%">
<thead><tr class="First Last">
<th class="Botrule Toprule" align="left" valign="top"><span class="Bold">Event</span></th>
<th class="Botrule Toprule" align="center" valign="top"><span class="Bold">Hydroxyurea<br>(N=152)</span></th>
<th class="Botrule Toprule" align="center" valign="top"><span class="Bold">Placebo<br>(N=147)</span></th>
<th class="Botrule Toprule" align="center" valign="top"><span class="Bold">Percent Change Versus Placebo</span></th>
<th class="Botrule Toprule" align="center" valign="top"><span class="Bold">P-value</span></th>
</tr></thead>
<tfoot><tr class="First Last"><td class="Botrule" align="left" colspan="5" valign="top">*Â Â Â A painful crisis was defined in the study as acute sickling-related <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> that resulted in a visit to a medical facility, that lasted more than 4 hours, and that required treatment with a parenteral narcotic or NSAID. Chest syndrome, <span class="product-label-link" type="condition" conceptid="315586" conceptname="Priapism">priapism</span>, and hepatic sequestration were also included in this definition.</td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Toprule" align="left"><p class="First">Median yearly rate of painful crises*</p></td>
<td class="Toprule"><p class="First">2.5</p></td>
<td class="Toprule"><p class="First">4.6</p></td>
<td class="Toprule"><p class="First">âˆ’46</p></td>
<td class="Toprule"><p class="First">=0.001</p></td>
</tr>
<tr>
<td align="left"><p class="First">Median yearly rate of painful crises requiring hospitalization</p></td>
<td><p class="First">1.0</p></td>
<td><p class="First">2.5</p></td>
<td><p class="First">âˆ’60</p></td>
<td><p class="First">=0.0027</p></td>
</tr>
<tr>
<td align="left"><p class="First">Median time to first painful crisis (months)</p></td>
<td><p class="First">2.76</p></td>
<td><p class="First">1.35</p></td>
<td><p class="First">+104</p></td>
<td><p class="First">=0.014</p></td>
</tr>
<tr>
<td align="left"><p class="First">Median time to second painful crisis (months)</p></td>
<td><p class="First">6.58</p></td>
<td><p class="First">4.13</p></td>
<td><p class="First">+59</p></td>
<td><p class="First">=0.0024</p></td>
</tr>
<tr>
<td align="left"><p class="First">Incidence of chest syndrome (# episodes)</p></td>
<td><p class="First">56</p></td>
<td><p class="First">101</p></td>
<td><p class="First">âˆ’45</p></td>
<td><p class="First">=0.003</p></td>
</tr>
<tr>
<td align="left"><p class="First">Number of patients transfused</p></td>
<td><p class="First">55</p></td>
<td><p class="First">79</p></td>
<td><p class="First">âˆ’30</p></td>
<td><p class="First">=0.002</p></td>
</tr>
<tr class="Last">
<td class="Botrule" align="left"><p class="First">Number of units of blood transfused</p></td>
<td class="Botrule"><p class="First">423</p></td>
<td class="Botrule"><p class="First">670</p></td>
<td class="Botrule"><p class="First">âˆ’37</p></td>
<td class="Botrule"><p class="First">=0.003</p></td>
</tr>
</tbody>
</table>
<p>In patients with SCA treated with hydroxyurea, fetal hemoglobin (HbF) increases 4 to 12 weeks after initiation of treatment. In general, average HbF levels correlate with dose and plasma level with possible plateauing at higher dosages.</p>
<p>A clear relation between reduction in crisis frequency and increased HbF or F-cell levels has not been demonstrated. The dose-related cytoreductive effects of hydroxyurea, particularly on <span class="product-label-link" type="condition" conceptid="4148615" conceptname="Neutrophil count">neutrophils</span>, was the factor most strongly correlated with reduced crisis frequency.</p>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="ID_8b8068d8-4385-4819-8395-3a3611a202a0"></a><a name="section-14"></a><p></p>
<h1>15 REFERENCES</h1>
<p class="First">OSHA. http://www.osha.gov/SLTC/hazardousdrugs/index.html.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="ID_4098f452-4f7f-4b57-921c-2f684b7dc208"></a><a name="section-15"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_b1b50540-34ed-426b-84c0-e73bfc819195"></a><a name="section-15.1"></a><p></p>
<h2>16.1Â Â How Supplied</h2>
<p class="First">DROXIA<span class="Sup">Â®</span> (hydroxyurea capsules, USP) is supplied in HDPE bottles with a plastic safety screw cap. Each bottle contains 60 capsules. DROXIA is supplied in the following strengths:</p>
<p>200 mg opaque blue-green capsules, marked in black ink with â€œ<span class="Bold">DROXIA</span>â€? and â€œ<span class="Bold">6335</span>â€? (NDC 0003-6335-17).</p>
<p>300 mg opaque purple capsules, marked in black ink with â€œ<span class="Bold">DROXIA</span>â€? and â€œ<span class="Bold">6336</span>â€? (NDC 0003-6336-17).</p>
<p>400 mg opaque reddish-orange capsules, marked in black ink with â€œ<span class="Bold">DROXIA</span>â€? and â€œ<span class="Bold">6337</span>â€? (NDC 0003-6337-17).</p>
</div>
<div class="Section" data-sectionCode="44425-7">
<a name="ID_8bf4bda6-a6ff-4f4b-97d8-9dadbab3a2f6"></a><a name="section-15.2"></a><p></p>
<h2>16.2Â Â Storage</h2>
<p class="First">Store at 25Â°C (77Â°F); excursions permitted to 15Â°C-30ÂºC (59Â°F-86ÂºF) [see USP Controlled Room Temperature]. Keep tightly closed.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_f9b0d034-d227-44b9-a8a8-e09b95a1b547"></a><a name="section-15.3"></a><p></p>
<h2>16.3Â Â Handling and Disposal</h2>
<p class="First">DROXIA is a cytotoxic drug. Follow applicable special handling and disposal procedures <span class="Italics">[see <a href="#ID_8b8068d8-4385-4819-8395-3a3611a202a0">References (15)</a>]</span>.</p>
<p>To decrease the risk of contact, advise caregivers to wear disposable gloves when handling DROXIA or bottles containing DROXIA. Wash hands with soap and water before and after contact with the bottle or capsules when handling DROXIA. Do not open DROXIA capsules. Avoid exposure to crushed or opened capsules. If contact with crushed or opened capsules occurs on the skin, wash affected area immediately and thoroughly with soap and water. If contact with crushed or opened capsules occurs on the eye(s), the affected area should be <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushed</span> thoroughly with water or isotonic eyewash designated for that purpose for at least 15 minutes. If the powder from the capsule is spilled, immediately wipe it up with a damp disposable towel and discard in a closed container, such as a plastic bag; as should the empty capsules. The spill areas should then be cleaned three times using a detergent solution followed by clean water. Keep the medication away from children and pets. Contact your doctor for instructions on how to dispose of outdated capsules.</p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="ID_0f9f80b1-41ff-4153-bb34-5b4c520f22a0"></a><a name="section-16"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<p class="First">Advise the patient to read the FDA-approved patient labeling (Patient Information).</p>
<dl>
<dt>â€¢</dt>
<dd>There is a risk of <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">myelosuppression</span>. Monitoring blood counts every two weeks throughout the duration of therapy should be emphasized to patients taking DROXIA <span class="Italics">[see <a href="#ID_502ba289-7d05-4156-a275-60c0f7767a52">Warnings and Precautions (5.1)</a>]</span>. Advise patients to report signs and symptoms of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> or <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> immediately.</dd>
<dt>â€¢</dt>
<dd>Advise patients that there is a risk of cutaneous vasculitic toxicities and secondary malignancies including <span class="product-label-link" type="condition" conceptid="315497" conceptname="Subacute leukemia">leukemia</span> and skin cancers. Advise use of sun protection <span class="Italics">[see <a href="#ID_3454f21b-4d96-4d30-ad0d-d82da5e7c794">Warnings and Precautions (5.2</a>, </span><span class="Italics"><a href="#ID_791e94df-3d3e-4c72-8b39-ea84c2fac6c8">5.4)</a></span><span class="Italics">]</span>.</dd>
<dt>â€¢</dt>
<dd>Advise females of reproductive potential of the potential risk to a fetus and to inform their healthcare provider of a known or suspected pregnancy. Advise females and males of reproductive potential to use contraception during and after treatment with DROXIA <span class="Italics">[see </span><span class="Italics"><a href="#ID_f192ba7c-bce6-4444-8461-a2cafd2183fd">Warnings and Precautions (5.3)</a></span><span class="Italics"> and <a href="#ID_45e3b835-f78e-412b-aa6d-68c56c9f65e7">Use in Specific Populations (8.1)</a>]</span>.</dd>
<dt>â€¢</dt>
<dd>Advise females to discontinue breastfeeding during treatment with DROXIA <span class="Italics">[see <a href="#ID_933a3c75-be9d-4768-8b00-0ebe868d4e13">Use in Specific Populations (8.3)</a>]</span>.</dd>
<dt>â€¢</dt>
<dd>Patients with <span class="product-label-link" type="condition" conceptid="439727" conceptname="Human immunodeficiency virus infection">HIV infection</span> should contact their physician for signs and symptoms of <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>, hepatic events, and <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">peripheral neuropathy</span> <span class="Italics">[see <a href="#ID_859b8b26-81d0-4ff1-b2ec-e5f9aaeaf9de">Warnings and Precautions (5.5)</a>]</span>.</dd>
</dl>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_788ef25e-b15a-42d4-9915-c7dd81ff0dd2"></a><a name="section-17"></a><p></p>
<p class="First">Manufactured for:<br>Bristol-Myers Squibb Company <br>Princeton, New Jersey 08543 USA <br><br>Product of Italy<br>1357793<br><br><br></p>
</div>
<div class="Section" data-sectionCode="42230-3">
<a name="ID_593de4ba-4e8a-4d1f-820c-25c126ff90a9"></a><a name="section-18"></a><p></p>
<h1>Patient Information <br>DROXIA<span class="Sup">Â®</span> (drock-SEE-yuh)<br>(hydroxyurea capsules, USP)</h1>
<p class="First">Read this Patient Information before you start using DROXIA (hydroxyurea) and each time you get a refill. There may be new information. This Medication Guide does not take the place of talking to your healthcare provider about your medical condition or treatment. You and your healthcare provider should talk about DROXIA when you start taking it and at regular checkups.</p>
<p><span class="Bold">What is the most important information I should know about DROXIA?</span></p>
<p><span class="Bold">DROXIA can cause serious side effects including:</span></p>
<dl>
<dt>â€¢</dt>
<dd>Low blood counts are common with DROXIA, including low red blood cells, white blood cells, and platelets, and can be severe and life-threatening. If your white blood cell count becomes very low, you are at increased risk for <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>. Your healthcare provider will check your blood cell counts before and during treatment with DROXIA. Your healthcare provider may change your dose or tell you to stop taking DROXIA if you have low blood cell counts. Tell your healthcare provider right away if you get any of the following symptoms:<dl>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span></dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span></dd>
<dt>â€¢</dt>
<dd>body <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">aches</span></dd>
<dt>â€¢</dt>
<dd>feeling very tired</dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span></dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span></dd>
</dl>
</dd>
<dt>â€¢</dt>
<dd>
<span class="Bold">Cancer.</span> Some people have developed cancer, such as <span class="product-label-link" type="condition" conceptid="315497" conceptname="Subacute leukemia">leukemia</span> and skin cancer, after taking DROXIA for a long time. Your healthcare provider will check you for cancer. You should protect your skin from the sun using sunblock, hats, and sun-protective clothing.</dd>
</dl>
<p><span class="Bold">DROXIA may cause harm to your unborn baby.</span></p>
<p><span class="Bold">For females taking DROXIA who can become pregnant:</span></p>
<dl>
<dt>â€¢</dt>
<dd>You should talk with your healthcare provider about the risks of DROXIA to your unborn child.</dd>
<dt>â€¢</dt>
<dd>You should use effective birth control during and after treatment with DROXIA for at least 30 days after treatment.</dd>
<dt>â€¢</dt>
<dd>Tell your healthcare provider right away if you become pregnant or think you may be pregnant.</dd>
</dl>
<p><span class="Bold">For males taking DROXIA:</span></p>
<dl>
<dt>â€¢</dt>
<dd>Males should use effective contraception during and after treatment with DROXIA for at least 1 year after therapy.</dd>
</dl>
<p><span class="Bold">For females NOT taking DROXIA who can become pregnant:</span></p>
<dl>
<dt>â€¢</dt>
<dd>You should ensure that your male partner, who is/has taken DROXIA, uses effective contraception during and after treatment for at least 1 year after therapy.</dd>
</dl>
<p><span class="Bold">DROXIA may cause fertility problems in males and females. Talk to your healthcare provider if this is a concern for you.</span></p>
<p>See â€œ<span class="Bold">What are the possible side effects of DROXIA?</span>â€? for more information about side effects.</p>
<p><span class="Bold">What is DROXIA?</span></p>
<p>DROXIA is a prescription medicine that is used to reduce the frequency of painful crises and reduce the need for blood transfusions in people with <span class="product-label-link" type="condition" conceptid="22281" conceptname="Hb SS disease">sickle cell anemia</span> with recurrent moderate to severe painful crises.</p>
<p>It is not known if DROXIA is safe and effective in children.</p>
<p><span class="Bold">Who should not take DROXIA?</span></p>
<p><span class="Bold">Do not take DROXIA if you are allergic to hydroxyurea or any of the ingredients in DROXIA.</span> See the end of this leaflet for a list of the ingredients in DROXIA.</p>
<p><span class="Bold">Before taking DROXIA, tell your healthcare provider about all of your medical conditions, including if you:</span></p>
<dl>
<dt>â€¢</dt>
<dd>have kidney problems or are receiving hemodialysis</dd>
<dt>â€¢</dt>
<dd>have liver problems</dd>
<dt>â€¢</dt>
<dd>have human <span class="product-label-link" type="condition" conceptid="433740" conceptname="Immunodeficiency disorder">immunodeficiency</span> virus (HIV). Taking DROXIA with certain HIV medicines can cause serious reactions and may lead to <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>.</dd>
<dt>â€¢</dt>
<dd>have increased level of uric acid in your blood (<span class="product-label-link" type="condition" conceptid="4147761" conceptname="Hyperuricemia">hyperuricemia</span>)</dd>
<dt>â€¢</dt>
<dd>have a history of receiving interferon therapy or are currently receiving interferon therapy</dd>
<dt>â€¢</dt>
<dd>are pregnant or plan to become pregnant. See â€œ<span class="Bold">What is the most important information I should know about DROXIA?</span>â€?</dd>
<dt>â€¢</dt>
<dd>are breastfeeding or plan to breastfeed. DROXIA can pass into your breast milk. Do not breastfeed during treatment with DROXIA. Talk to your healthcare provider about the best way to feed your baby.</dd>
</dl>
<p><span class="Bold">Tell your healthcare provider about all the medicines you take</span>, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Especially tell your healthcare provider if you take an antiretroviral medicine. Taking DROXIA with certain antiretroviral medicines can cause serious side effects and may lead to <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>.</p>
<p><span class="Bold">How should I take DROXIA?</span></p>
<dl>
<dt>â€¢</dt>
<dd>Take DROXIA exactly as your healthcare provider tells you.</dd>
<dt>â€¢</dt>
<dd>DROXIA is taken 1 time a day.</dd>
<dt>â€¢</dt>
<dd>Your healthcare provider will determine the right starting dose of DROXIA for you based on your weight. Your dose will then be increased slowly to your maximum tolerated dose (a dose that does not produce severely low blood counts).</dd>
<dt>â€¢</dt>
<dd>If you take too much DROXIA, call your healthcare provider or go to the nearest hospital emergency room right away.</dd>
<dt>â€¢</dt>
<dd>DROXIA is a medicine that must be handled with care. People who are not taking DROXIA should not be exposed to it. To decrease the risk of exposure, you or your caregivers should do the following when handling DROXIA:<dl>
<dt>â€¢</dt>
<dd>Wear disposable gloves when handling DROXIA capsules or bottles containing DROXIA.</dd>
<dt>â€¢</dt>
<dd>Wash your hands before and after handling DROXIA capsules or bottles containing DROXIA.</dd>
<dt>â€¢</dt>
<dd>Do not open the capsules.</dd>
<dt>â€¢</dt>
<dd>Avoid contact with crushed or opened capsules. If contact from crushed or opened capsules happens on the skin, wash the skin area right away with soap and water. If contact from crushed or opened capsules happens on the eye(s), flush the eye(s) thoroughly with water or isotonic eyewash designated for that purpose for at least 15 minutes.</dd>
<dt>â€¢</dt>
<dd>If the powder from the capsule is spilled, wipe it up right away with a damp disposable towel, and throw it away in a closed container, such as a plastic bag; as should the empty capsules. The spill areas should then be cleaned three times using a detergent solution followed by clean water.</dd>
</dl>
</dd>
</dl>
<p><span class="Bold">What are the possible side effects of DROXIA?</span></p>
<p>DROXIA may cause serious side effects, including:</p>
<dl>
<dt>â€¢</dt>
<dd>See â€œ<span class="Bold">What is the most important information I should know about DROXIA?</span>â€?</dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="4262920" conceptname="Skin ulcer">Skin ulcers</span> have happened in people who take DROXIA. This has occurred most often in people who receive interferon therapy or have a history of interferon therapy. Your healthcare provider will stop treatment with DROXIA if you develop any <span class="product-label-link" type="condition" conceptid="4262920" conceptname="Skin ulcer">skin ulcers</span>.</dd>
</dl>
<p><span class="Bold">The most common side effects of DROXIA include:</span></p>
<dl>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">hair loss</span></dd>
<dt>â€¢</dt>
<dd>enlarged red blood cells (<span class="product-label-link" type="condition" conceptid="4248718" conceptname="Macrocytosis">macrocytosis</span>). <span class="product-label-link" type="condition" conceptid="4248718" conceptname="Macrocytosis">Macrocytosis</span> can make it difficult to detect a decrease of folic acid in people taking DROXIA. Your healthcare provider may prescribe a folic acid supplement for you.</dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span></dd>
<dt>â€¢</dt>
<dd>brown or black colored nails</dd>
</dl>
<p>These are not all the possible side effects of DROXIA. For more information, ask your healthcare provider or pharmacist.</p>
<p>Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.</p>
<p><span class="Bold">How Should I store DROXIA?</span></p>
<dl>
<dt>â€¢</dt>
<dd>Store DROXIA at room temperature between 68Â°F to 77Â°F (20Â°C to 25Â°C). Keep the bottle tightly closed.</dd>
<dt>â€¢</dt>
<dd>Call your healthcare provider for instructions on how to throw away (dispose of) DROXIA that is out of date or no longer needed.</dd>
</dl>
<p><span class="Bold">Keep DROXIA and all medicines out of the reach of children. Keep DROXIA away from pets.</span></p>
<p><span class="Bold">General information about the safe and effective use of DROXIA</span></p>
<p>Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use DROXIA for a condition for which it was not prescribed. Do not give DROXIA to other people, even if they have the same symptoms you have. It may harm them. You can ask your healthcare provider or pharmacist for information about DROXIA that is written for health professionals.</p>
<p><span class="Bold">What are the ingredients of DROXIA?</span></p>
<p><span class="Bold">Active ingredient:</span> hydroxyurea</p>
<p><span class="Bold">Inactive ingredients:</span> citric acid, gelatin, lactose, magnesium stearate, sodium phosphate, titanium dioxide, and capsule colorants: FD&amp;C Blue No. 1 and FD&amp;C Green No. 3 (200 mg capsules); D&amp;C Red No. 28, D&amp;C Red No. 33, and FD&amp;C Blue No. 1 (300 mg capsules); D&amp;C Red No. 28, D&amp;C Red No. 33, and D&amp;C Yellow No. 10 (400 mg capsules).</p>
<p>Manufactured for: Bristol-Myers Squibb Company, Princeton, New Jersey 08543 USA<br>Product of Italy</p>
<p>For more information, go to www.BMS.com or call 1-800-721-5072.<br>This Patient Information has been approved by the U.S. Food and Drug Administration.</p>
<p><br><br>1357793<br>Revised: July 2015</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="ID_795ae172-a53e-4972-8452-57ad69a6d0e7"></a><a name="section-19"></a><p></p>
<h1>DROXIA 200 mg capsules Representative Packaging</h1>
<p class="First">See <span class="Bold">How Supplied</span> section for a complete list of available packages of DROXIA.</p>
<p><span class="Bold">60 CAPSULES</span><br><span class="Bold">NDC 0003-6335-17</span><br><span class="Bold">DROXIA<span class="Sup">Â®</span></span><br><span class="Bold">(hydroxyurea capsules, USP)</span><br><span class="Bold">200 mg</span> per capsule<br><span class="Bold">Rx only</span><br><span class="Bold">Bristol-Myers Squibb</span></p>
<div class="Figure">
<a name="id16926719"></a><img alt="Droxia 200 mg Bottle Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=740e054b-faac-7c27-f06d-a56efb699355&amp;name=droxia-200mg-label.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="ID_5e79d087-c703-473c-9e91-e6a617a8a4f7"></a><a name="section-20"></a><p></p>
<h1>DROXIA 300 mg capsules Representative Packaging</h1>
<p class="First"><span class="Bold">60 CAPSULES</span><br><span class="Bold">NDC 0003-6336-17</span><br><span class="Bold">DROXIA<span class="Sup">Â®</span></span><br><span class="Bold">(hydroxyurea capsules, USP)</span><br><span class="Bold">300 mg</span> per capsule<br><span class="Bold">Rx only</span><br><span class="Bold">Bristol-Myers Squibb</span></p>
<div class="Figure">
<a name="id16925677"></a><img alt="Droxia 300 mg Bottle Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=740e054b-faac-7c27-f06d-a56efb699355&amp;name=droxia-300mg-label.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="ID_dd58c538-71d9-4b5b-a428-b9fc9801e70d"></a><a name="section-21"></a><p></p>
<h1>DROXIA 400 mg capsules Representative Packaging</h1>
<p class="First"><span class="Bold">60 CAPSULES</span><br><span class="Bold">NDC 0003-6337-17</span><br><span class="Bold">DROXIA<span class="Sup">Â®</span></span><br><span class="Bold">(hydroxyurea capsules, USP)</span><br><span class="Bold">400 mg</span> per capsule<br><span class="Bold">Rx only</span><br><span class="Bold">Bristol-Myers Squibb</span></p>
<div class="Figure">
<a name="id16924635"></a><img alt="Droxia 400 mg Bottle Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=740e054b-faac-7c27-f06d-a56efb699355&amp;name=droxia-400mg-label.jpg">
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>DROXIAÂ 		
					</strong><br><span class="contentTableReg">hydroxyurea capsule</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0003-6335</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>hydroxyurea</strong> (hydroxyurea) </td>
<td class="formItem">hydroxyurea</td>
<td class="formItem">200Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>citric acid monohydrate</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>gelatin</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>lactose</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>magnesium stearate</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>sodium phosphate</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>titanium dioxide</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C Blue No. 1</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FD&amp;C Green No. 3</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">TURQUOISE (blue-green) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">CAPSULE</td>
<td class="formLabel">Size</td>
<td class="formItem">16mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">DROXIA;6335;DROXIA;6335</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0003-6335-17</td>
<td class="formItem">60  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem">07/16/2015</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA016295</td>
<td class="formItem">06/01/2009</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>DROXIAÂ 		
					</strong><br><span class="contentTableReg">hydroxyurea capsule</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0003-6336</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>hydroxyurea</strong> (hydroxyurea) </td>
<td class="formItem">hydroxyurea</td>
<td class="formItem">300Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>citric acid monohydrate</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>gelatin</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>lactose</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>magnesium stearate</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>sodium phosphate</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>titanium dioxide</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>D&amp;C Red No. 28</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>D&amp;C Red No. 33</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C Blue No. 1</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">PURPLE</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">CAPSULE</td>
<td class="formLabel">Size</td>
<td class="formItem">19mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">DROXIA;6336;DROXIA;6336</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0003-6336-17</td>
<td class="formItem">60  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem">07/16/2015</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA016295</td>
<td class="formItem">06/01/2009</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>DROXIAÂ 		
					</strong><br><span class="contentTableReg">hydroxyurea capsule</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0003-6337</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>hydroxyurea</strong> (hydroxyurea) </td>
<td class="formItem">hydroxyurea</td>
<td class="formItem">400Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>citric acid monohydrate</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>gelatin</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>lactose</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>magnesium stearate</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>sodium phosphate</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>titanium dioxide</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>D&amp;C Red No. 28</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>D&amp;C Red No. 33</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>D&amp;C Yellow No. 10</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">ORANGE</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">CAPSULE</td>
<td class="formLabel">Size</td>
<td class="formItem">22mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">DROXIA;6337;DROXIA;6337</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0003-6337-17</td>
<td class="formItem">60  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem">07/16/2015</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA016295</td>
<td class="formItem">06/01/2009</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>E.R. Squibb &amp; Sons, L.L.C.
							(011550092)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 7/2015<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>2d5be09f-fd95-47d9-ad64-7d0b925161ea</div>
<div>Set id: 740e054b-faac-7c27-f06d-a56efb699355</div>
<div>Version: 7</div>
<div>Effective Time: 20150716</div>
</div>
</div>Â <div class="DistributorName">E.R. Squibb &amp; Sons, L.L.C.</div></p>
</body></html>
